hepurposeofthisreportwastoupdatethe2006InternationalLeagueAgainstEpilepsy(ILAE)reportandidentifythelevelofevidenceforlong-termefficacyoreffectivenessforantiepilepticdrugs(AEDs)asinitialmonotherapyforpatientswithnewlydiagnosedoruntreatedepilepsy.AllapplicablearticlesfromJuly2005untilMarch2012wereidentified,evaluated,andcombinedwiththepreviousysis(Glauseretal.,2006)toprovideacomprehensiveupdate.
Thepriorysismethodologywasutilizedwiththreemodifications:(1)thedetectablenoninferiorityboundaryapproachwasdroppedandbothfailedsuperioritystudiesandprespecifiednoninferioritystudieswereyzedusinganoninferiorityapproach,(2)thedefinitionofanadequatecomparatorwasclarifiedandnowincludesanabsoluteminimumpointestimateforefficacy/effectiveness,and(3)therelationshiptablebetweenclinicaltrialratings,levelofevidence,andconclusionsnolongerincludesarecommendationcolumntoreinforcethatthisreviewofefficacy/evidenceforspecificseizuretypesdoesnotimplytreatmentrecommendations.
Thisevidencereviewcontainsoneclarification:ThecommissionhasdeterminedthatclassIsuperioritystudiescanbedesignedtodetectuptoa20?solute(ratherthanrelative)differenceinthepointestimateofefficacy/effectivenessbetweenstudytreatmentandcomparatorusinganintent-to-treatysis.SinceJuly,2005,threeclassIrandomizedcontrolledtrials(RCT)and11classIIIRCTshebeenpublished.Thecombinedysis(1940-2012)nowincludesatotalof64RCTs(7withclassIevidence,2withclassIIevidence)and11meta-yses.
Newefficacy/effectivenessfindingsincludethefollowing:levetiracetamandzonisamidehelevelAevidenceinswithpartialonsetseizuresandbothethosuximideandvalproicacidhelevelAevidenceinchildrenwithchildhoodabsenceepilepsy.
Therearenomajorchangesinthelevelofevidenceforanyothersubgroup.LevetiracetamandzonisamidejoincarbamazepineandphenytoinwithlevelAefficacy/effectivenessevidenceasinitialmonotherapyforswithpartialonsetseizures.AlthoughethosuximideandvalproicacidnowhelevelAefficacy/effectivenessevidenceasinitialmonotherapyforchildrenwithabsenceseizures,therecontinuestobeanalarminglackofwelldesigned,properlyconductedepilepsyRCTsforpatientswithgeneralizedseizures/epilepsiesandinchildreningeneral.
Thesefindingsreinforcetheneedformulticenter,multinationaleffortstodesign,conduct,andyzefutureclinicallyrelevantadequatelydesignedRCTs.Whenselectingapatient'sAED,allrelevantvariablesandnotjustefficacyandeffectivenessshouldbeconsidered.
查看信源地址
编辑:jiang- 2022-05-10癫痫病的疾病有哪些呢
- 2022-04-27OCC 2020 | 苏晞:血栓形成患者血栓整体管理的目标和决策
- 2022-04-13控制癫痫患者再次抽搐,不包括可选药物?
- 2022-04-11由于医生的原因,物「沉默」而且很难进入处方
- 2022-04-11Rheumatology:甘氨酸通过SAM介导的GPX4类风湿性关节炎启动子甲基化铁浓度变化研究
- 2022-04-06预测癫痫患者再入院风险
- 控制癫痫患者再次抽搐,不包括可选药物?
- 综述:癫痫持续状态诊治最新进展
- 由于医生的原因,物「沉默」而且很难进入处方
- Rheumatology:甘氨酸通过SAM介导的GPX4类风湿性关节炎启动子甲基化铁浓度变化研究
- 著名女演员愤怒地告诉莆田妇科医院 要求在全国媒体上公开道歉
- 预测癫痫患者再入院风险
- 运动或帮助保护1型糖尿病患者β细胞功能
- 癫痫猝死:凶手是谁?
- 美国FDA关于坏死因子阻滞剂、硫唑嘌呤和/或硫唑嘌呤的安全性更新
- 乳腺癌早期症状 乳腺癌早期出现的五种信号
- 癫痫病的最新治疗方法 癫痫发作的急救
- UCB的Vimpat癫痫新适应症在美国获批
- 癫痫治疗障碍仍难以克服
- 调查展开!没生却被推上手术台?安康老品牌男科摊
- NICE推荐将Elmiron(戊糖多钠)治疗膀胱疼痛综合征
- 儿童癫痫的早期症状 癫痫的原因
- 抗癫痫药物预防新发癫痫:任重而道远
- 元宵节吃汤圆送灯
- JAMA Neurology:左乙拉西坦对阿尔茨海默病患者的认知功能有影响,不伴有癫痫活动
- 精囊炎是怎么回事?3个症状要警惕,3个治疗要点要记住
- 2013国际抗癫痫联合会抗癫痫药用指南
- 【用药情报站】临床应用应听取各种药种药物禁忌证?
- FDA批准塞尔基因Otezla治疗银屑病性关节炎
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 纤毛菌是革兰氏阴性厌氧菌还是真菌?
- 不注意这些问题,吃多少药都没用!
- 癫痫会遗传吗 癫痫的治疗方法
- 信达生物贝伐珠单抗生物类似药-达游同上市
- 睡突然抽搐一下 新生儿睡觉抽搐怎么办
- 女性体检 定期体检认清妇科亚健康
- 导致癫痫病的病因有哪些
- 癫痫病的心脏病症状有哪些
- 癫痫频繁发作伤害极大,如何减少癫痫频发? 日常生活之中这样做!
- 癫痫病只不过有哪几种类型呢 癫痫的症状有什么
- 北京天坛医院张教授跻身“北京学者”
- 小儿癫痫的早期征状 癫痫的原因
- 水果虽难看有可能更健康
- 癫痫病是怎么引起的得病 癫痫病的病因是什么
- 专家谈有哪些癫痫病的有鉴于此
- 症状性癫痫外科手术费用要多少钱